nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—CYP2C19—Ifosfamide—testicular cancer	0.111	0.367	CbGbCtD
Gliclazide—CYP2C9—Ifosfamide—testicular cancer	0.092	0.305	CbGbCtD
Gliclazide—ALB—Methotrexate—testicular cancer	0.0539	0.179	CbGbCtD
Gliclazide—CYP2C9—Cisplatin—testicular cancer	0.0448	0.149	CbGbCtD
Gliclazide—Fatigue—Etoposide—testicular cancer	0.000478	0.000684	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—testicular cancer	0.000477	0.000683	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—testicular cancer	0.000475	0.000679	CcSEcCtD
Gliclazide—Pain—Etoposide—testicular cancer	0.000474	0.000678	CcSEcCtD
Gliclazide—Constipation—Etoposide—testicular cancer	0.000474	0.000678	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—testicular cancer	0.000473	0.000677	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—testicular cancer	0.000473	0.000677	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.00047	0.000672	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—testicular cancer	0.000467	0.000668	CcSEcCtD
Gliclazide—Sweating—Epirubicin—testicular cancer	0.000467	0.000668	CcSEcCtD
Gliclazide—Dizziness—Ifosfamide—testicular cancer	0.000464	0.000664	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—testicular cancer	0.000464	0.000663	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000461	0.00066	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—testicular cancer	0.00046	0.000659	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—testicular cancer	0.00046	0.000658	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—testicular cancer	0.000459	0.000657	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—testicular cancer	0.000457	0.000654	CcSEcCtD
Gliclazide—Feeling abnormal—Etoposide—testicular cancer	0.000456	0.000653	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—testicular cancer	0.000456	0.000652	CcSEcCtD
Gliclazide—Nausea—Dactinomycin—testicular cancer	0.000455	0.000651	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—testicular cancer	0.000454	0.00065	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—testicular cancer	0.000453	0.000648	CcSEcCtD
Gliclazide—Gastrointestinal pain—Etoposide—testicular cancer	0.000453	0.000648	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—testicular cancer	0.00045	0.000645	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—testicular cancer	0.00045	0.000644	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000447	0.000639	CcSEcCtD
Gliclazide—Vomiting—Ifosfamide—testicular cancer	0.000446	0.000638	CcSEcCtD
Gliclazide—Hypersensitivity—Cisplatin—testicular cancer	0.000445	0.000638	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—testicular cancer	0.000445	0.000637	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—testicular cancer	0.000443	0.000634	CcSEcCtD
Gliclazide—Rash—Ifosfamide—testicular cancer	0.000442	0.000633	CcSEcCtD
Gliclazide—Dermatitis—Ifosfamide—testicular cancer	0.000442	0.000632	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—testicular cancer	0.000442	0.000632	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000442	0.000632	CcSEcCtD
Gliclazide—Urticaria—Etoposide—testicular cancer	0.00044	0.00063	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—testicular cancer	0.000439	0.000628	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—testicular cancer	0.000438	0.000627	CcSEcCtD
Gliclazide—Abdominal pain—Etoposide—testicular cancer	0.000438	0.000627	CcSEcCtD
Gliclazide—Body temperature increased—Etoposide—testicular cancer	0.000438	0.000627	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—testicular cancer	0.000438	0.000627	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—testicular cancer	0.000438	0.000627	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—testicular cancer	0.000437	0.000626	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—testicular cancer	0.000436	0.000625	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—testicular cancer	0.000435	0.000623	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—testicular cancer	0.000435	0.000622	CcSEcCtD
Gliclazide—Asthenia—Cisplatin—testicular cancer	0.000434	0.000621	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—testicular cancer	0.000434	0.000621	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—testicular cancer	0.000432	0.000618	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—testicular cancer	0.000431	0.000616	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000426	0.00061	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—testicular cancer	0.000425	0.000608	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—testicular cancer	0.000423	0.000605	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—testicular cancer	0.000421	0.000603	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—testicular cancer	0.00042	0.000602	CcSEcCtD
Gliclazide—Chills—Methotrexate—testicular cancer	0.000419	0.0006	CcSEcCtD
Gliclazide—Nausea—Ifosfamide—testicular cancer	0.000417	0.000596	CcSEcCtD
Gliclazide—Diarrhoea—Cisplatin—testicular cancer	0.000414	0.000592	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—testicular cancer	0.000413	0.000591	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—testicular cancer	0.000412	0.000589	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—testicular cancer	0.000409	0.000586	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—testicular cancer	0.000408	0.000585	CcSEcCtD
Gliclazide—Hypersensitivity—Etoposide—testicular cancer	0.000408	0.000584	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—testicular cancer	0.000408	0.000583	CcSEcCtD
Gliclazide—Erythema—Methotrexate—testicular cancer	0.000407	0.000582	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—testicular cancer	0.000407	0.000582	CcSEcCtD
Gliclazide—Flushing—Epirubicin—testicular cancer	0.000406	0.000581	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—testicular cancer	0.000405	0.00058	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—testicular cancer	0.000404	0.000579	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—testicular cancer	0.000402	0.000576	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—testicular cancer	0.000401	0.000574	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—testicular cancer	0.000398	0.00057	CcSEcCtD
Gliclazide—Asthenia—Etoposide—testicular cancer	0.000397	0.000569	CcSEcCtD
Gliclazide—Back pain—Methotrexate—testicular cancer	0.000393	0.000563	CcSEcCtD
Gliclazide—Chills—Epirubicin—testicular cancer	0.000392	0.000561	CcSEcCtD
Gliclazide—Pruritus—Etoposide—testicular cancer	0.000392	0.000561	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—testicular cancer	0.00039	0.000559	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—testicular cancer	0.00039	0.000558	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—testicular cancer	0.000384	0.00055	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—testicular cancer	0.000383	0.000548	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—testicular cancer	0.000382	0.000547	CcSEcCtD
Gliclazide—Rash—Cisplatin—testicular cancer	0.000381	0.000546	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—testicular cancer	0.000381	0.000545	CcSEcCtD
Gliclazide—Erythema—Epirubicin—testicular cancer	0.00038	0.000545	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—testicular cancer	0.00038	0.000545	CcSEcCtD
Gliclazide—Diarrhoea—Etoposide—testicular cancer	0.000379	0.000542	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—testicular cancer	0.000378	0.000541	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—testicular cancer	0.000377	0.00054	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—testicular cancer	0.000377	0.00054	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—testicular cancer	0.000376	0.000538	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—testicular cancer	0.000375	0.000537	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—testicular cancer	0.000375	0.000537	CcSEcCtD
Gliclazide—Tension—Epirubicin—testicular cancer	0.000373	0.000534	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—testicular cancer	0.00037	0.000529	CcSEcCtD
Gliclazide—Back pain—Epirubicin—testicular cancer	0.000368	0.000527	CcSEcCtD
Gliclazide—Malaise—Methotrexate—testicular cancer	0.000367	0.000525	CcSEcCtD
Gliclazide—Dizziness—Etoposide—testicular cancer	0.000366	0.000524	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—testicular cancer	0.000364	0.000521	CcSEcCtD
Gliclazide—Chills—Doxorubicin—testicular cancer	0.000363	0.000519	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—testicular cancer	0.000361	0.000517	CcSEcCtD
Gliclazide—Nausea—Cisplatin—testicular cancer	0.000359	0.000514	CcSEcCtD
Gliclazide—Cough—Methotrexate—testicular cancer	0.000355	0.000508	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—testicular cancer	0.000354	0.000507	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—testicular cancer	0.000353	0.000505	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—testicular cancer	0.000352	0.000504	CcSEcCtD
Gliclazide—Vomiting—Etoposide—testicular cancer	0.000352	0.000504	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—testicular cancer	0.000352	0.000504	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—testicular cancer	0.000352	0.000504	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—testicular cancer	0.000352	0.000503	CcSEcCtD
Gliclazide—Agitation—Epirubicin—testicular cancer	0.00035	0.0005	CcSEcCtD
Gliclazide—Rash—Etoposide—testicular cancer	0.000349	0.0005	CcSEcCtD
Gliclazide—Dermatitis—Etoposide—testicular cancer	0.000349	0.000499	CcSEcCtD
Gliclazide—Headache—Etoposide—testicular cancer	0.000347	0.000497	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—testicular cancer	0.000347	0.000496	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—testicular cancer	0.000346	0.000495	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—testicular cancer	0.000346	0.000495	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—testicular cancer	0.000346	0.000495	CcSEcCtD
Gliclazide—Tension—Doxorubicin—testicular cancer	0.000345	0.000494	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000344	0.000492	CcSEcCtD
Gliclazide—Malaise—Epirubicin—testicular cancer	0.000343	0.000491	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—testicular cancer	0.000342	0.000489	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—testicular cancer	0.000342	0.000489	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—testicular cancer	0.000341	0.000487	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—testicular cancer	0.000341	0.000487	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—testicular cancer	0.000336	0.000481	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—testicular cancer	0.000335	0.000479	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—testicular cancer	0.000334	0.000479	CcSEcCtD
Gliclazide—Cough—Epirubicin—testicular cancer	0.000332	0.000475	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—testicular cancer	0.00033	0.000472	CcSEcCtD
Gliclazide—Infection—Methotrexate—testicular cancer	0.00033	0.000472	CcSEcCtD
Gliclazide—Nausea—Etoposide—testicular cancer	0.000329	0.000471	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—testicular cancer	0.000328	0.00047	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—testicular cancer	0.000327	0.000467	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—testicular cancer	0.000325	0.000466	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—testicular cancer	0.000325	0.000466	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—testicular cancer	0.000325	0.000465	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—testicular cancer	0.000324	0.000464	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—testicular cancer	0.000324	0.000464	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—testicular cancer	0.000324	0.000464	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—testicular cancer	0.000324	0.000463	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—testicular cancer	0.000323	0.000462	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—testicular cancer	0.000322	0.000461	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000322	0.00046	CcSEcCtD
Gliclazide—Hyperhidrosis—Methotrexate—testicular cancer	0.000321	0.000459	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—testicular cancer	0.00032	0.000458	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—testicular cancer	0.000317	0.000454	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—testicular cancer	0.000317	0.000453	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—testicular cancer	0.000315	0.000451	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—testicular cancer	0.000313	0.000448	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—testicular cancer	0.000311	0.000445	CcSEcCtD
Gliclazide—Hypotension—Methotrexate—testicular cancer	0.00031	0.000444	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—testicular cancer	0.000309	0.000443	CcSEcCtD
Gliclazide—Infection—Epirubicin—testicular cancer	0.000308	0.000442	CcSEcCtD
Gliclazide—Cough—Doxorubicin—testicular cancer	0.000307	0.00044	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—testicular cancer	0.000305	0.000437	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—testicular cancer	0.000305	0.000436	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—testicular cancer	0.000304	0.000435	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—testicular cancer	0.000304	0.000435	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—testicular cancer	0.000303	0.000434	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000302	0.000433	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—testicular cancer	0.000302	0.000432	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—testicular cancer	0.0003	0.00043	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—testicular cancer	0.0003	0.00043	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—testicular cancer	0.0003	0.000429	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—testicular cancer	0.0003	0.000429	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—testicular cancer	0.0003	0.000429	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—testicular cancer	0.000299	0.000427	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—testicular cancer	0.000298	0.000426	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000298	0.000426	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—testicular cancer	0.000296	0.000424	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—testicular cancer	0.000296	0.000423	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—testicular cancer	0.000295	0.000422	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—testicular cancer	0.000293	0.00042	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—testicular cancer	0.000292	0.000418	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—testicular cancer	0.00029	0.000415	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—testicular cancer	0.00029	0.000415	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000286	0.00041	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—testicular cancer	0.000286	0.000409	CcSEcCtD
Gliclazide—Infection—Doxorubicin—testicular cancer	0.000285	0.000409	CcSEcCtD
Gliclazide—Pain—Methotrexate—testicular cancer	0.000284	0.000406	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000283	0.000405	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—testicular cancer	0.000282	0.000403	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—testicular cancer	0.000281	0.000403	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—testicular cancer	0.000281	0.000402	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—testicular cancer	0.00028	0.000401	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—testicular cancer	0.000279	0.000399	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—testicular cancer	0.000279	0.000399	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—testicular cancer	0.000278	0.000398	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—testicular cancer	0.000277	0.000396	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—testicular cancer	0.000276	0.000395	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—testicular cancer	0.000273	0.000391	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—testicular cancer	0.000273	0.000391	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—testicular cancer	0.000271	0.000388	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—testicular cancer	0.000268	0.000384	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000268	0.000384	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—testicular cancer	0.000268	0.000383	CcSEcCtD
Gliclazide—Pain—Epirubicin—testicular cancer	0.000266	0.00038	CcSEcCtD
Gliclazide—Constipation—Epirubicin—testicular cancer	0.000266	0.00038	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—testicular cancer	0.000264	0.000377	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—testicular cancer	0.000262	0.000375	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—testicular cancer	0.000262	0.000375	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000262	0.000375	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—testicular cancer	0.00026	0.000372	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—testicular cancer	0.000258	0.000369	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—testicular cancer	0.000256	0.000367	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—testicular cancer	0.000256	0.000366	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—testicular cancer	0.000255	0.000366	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—testicular cancer	0.000254	0.000363	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—testicular cancer	0.000253	0.000362	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000248	0.000355	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—testicular cancer	0.000248	0.000355	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—testicular cancer	0.000247	0.000353	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—testicular cancer	0.000246	0.000352	CcSEcCtD
Gliclazide—Pain—Doxorubicin—testicular cancer	0.000246	0.000352	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—testicular cancer	0.000245	0.000351	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—testicular cancer	0.000245	0.000351	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—testicular cancer	0.000244	0.00035	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—testicular cancer	0.000238	0.000341	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—testicular cancer	0.000237	0.000339	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000235	0.000336	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—testicular cancer	0.000235	0.000336	CcSEcCtD
Gliclazide—Hypersensitivity—Epirubicin—testicular cancer	0.000229	0.000327	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—testicular cancer	0.000228	0.000327	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—testicular cancer	0.000227	0.000325	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—testicular cancer	0.000227	0.000325	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—testicular cancer	0.000227	0.000325	CcSEcCtD
Gliclazide—Asthenia—Epirubicin—testicular cancer	0.000223	0.000319	CcSEcCtD
Gliclazide—Pruritus—Epirubicin—testicular cancer	0.00022	0.000314	CcSEcCtD
Gliclazide—Dizziness—Methotrexate—testicular cancer	0.000219	0.000314	CcSEcCtD
Gliclazide—Diarrhoea—Epirubicin—testicular cancer	0.000212	0.000304	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—testicular cancer	0.000212	0.000303	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—testicular cancer	0.000211	0.000302	CcSEcCtD
Gliclazide—Rash—Methotrexate—testicular cancer	0.000209	0.000299	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—testicular cancer	0.000209	0.000299	CcSEcCtD
Gliclazide—Headache—Methotrexate—testicular cancer	0.000208	0.000297	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—testicular cancer	0.000206	0.000295	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—testicular cancer	0.000205	0.000294	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—testicular cancer	0.000203	0.000291	CcSEcCtD
Gliclazide—Vomiting—Epirubicin—testicular cancer	0.000197	0.000283	CcSEcCtD
Gliclazide—Nausea—Methotrexate—testicular cancer	0.000197	0.000282	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—testicular cancer	0.000197	0.000281	CcSEcCtD
Gliclazide—Rash—Epirubicin—testicular cancer	0.000196	0.00028	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—testicular cancer	0.000196	0.00028	CcSEcCtD
Gliclazide—Headache—Epirubicin—testicular cancer	0.000195	0.000278	CcSEcCtD
Gliclazide—Dizziness—Doxorubicin—testicular cancer	0.00019	0.000272	CcSEcCtD
Gliclazide—Nausea—Epirubicin—testicular cancer	0.000184	0.000264	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—testicular cancer	0.000183	0.000261	CcSEcCtD
Gliclazide—Rash—Doxorubicin—testicular cancer	0.000181	0.000259	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—testicular cancer	0.000181	0.000259	CcSEcCtD
Gliclazide—Headache—Doxorubicin—testicular cancer	0.00018	0.000258	CcSEcCtD
Gliclazide—Nausea—Doxorubicin—testicular cancer	0.000171	0.000244	CcSEcCtD
